voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen (Gilead Sciences)
Structured Review

Voxilaprevir Hcv Ns3 4a Protease Inhibitor Chronic Hcv After Selected Prior Daa Failure Us Fda Approved In The Fixed Dose Vosevi Rescue Regimen, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 178 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/selection/Vosevi/pmc13748950-6-0-17
Average 97 stars, based on 178 article reviews
Images
1) Product Images from "Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects"
Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects
Journal: MedComm
doi: 10.1002/mco2.71024
Figure Legend Snippet: Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
Techniques Used: Protease Inhibitor
Related Articles
Virus:Article Title: Hepatitis C Virus Elimination: So Close, So Far? Article Snippet: 21 22 The advent of highly effective direct-acting antivirals (DAAs) has transformed hepatitis 23 C virus (HCV) infection into a curable disease, with cure rates exceeding 95% across viral 24 genotypes and clinical settings.. Along with simplified, short-course treatment regimens and 25 significant advancements in diagnostic technologies, these therapeutic breakthroughs have 26 made eliminating HCV as a public health concern, as defined by the World Health 27 Organization, a realistic goal.. However, despite this progress, global advances toward 28 elimination have fallen short of expectations. Protease Inhibitor:Article Title: Hepatitis C Virus Elimination: So Close, So Far? Article Snippet: 21 22 The advent of highly effective direct-acting antivirals (DAAs) has transformed hepatitis 23 C virus (HCV) infection into a curable disease, with cure rates exceeding 95% across viral 24 genotypes and clinical settings.. Along with simplified, short-course treatment regimens and 25 significant advancements in diagnostic technologies, these therapeutic breakthroughs have 26 made eliminating HCV as a public health concern, as defined by the World Health 27 Organization, a realistic goal.. However, despite this progress, global advances toward 28 elimination have fallen short of expectations. Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects Article Snippet: Sofosbuvir Nucleotide prodrug; HCV NS5B polymerase inhibitor; chronic HCV; US FDA‐approved alone and in fixed‐dose DAA combinations , C 22 H 29 FN 3 O 9 P; CID 45375808 , Velpatasvir HCV NS5A inhibitor; chronic HCV; US FDA‐approved with sofosbuvir (Epclusa) and in sofosbuvir/velpatasvir/voxilaprevir (Vosevi) , C 49 H 54 N 8 O 8 ; CID 67683363. .. other:Article Title: In Silico Characterization of Two Human Pegivirus Proteins Highlights Similarities with Hepatitis C Virus and Possible Therapeutic Repurposing Article Snippet: Article Title: Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder Article Snippet: |
